AMRUTAJAN HEALTH LTD
AMRUTANJAN · General/Diversified · NSE
₹557
Current Market Price
Fair Value (DCF)
₹358
Discount to FV
-35.6%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
63%
ROE
15.6%
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹1,610 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.7%
Return on capital employed
EV / EBITDA
16.8×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
315.2×
EBIT covers interest
Current Ratio
3.44×
Short-term liquidity
Asset Turnover
1.19×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹556.95
Bear case
Discount -185.0%
Base case
Discount -55.4%
Bull case
Discount -29.5%
Ratio Trends
AMRUTANJAN · last 10 annual periods
ROE
15.6%
ROCE
22.7%
Operating Margin
—
Debt / Equity
0.00×
PE
24.6×
EV / EBITDA
16.8×
Historical Financials
AMRUTANJAN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹405 Cr | ₹378 Cr | ₹420 Cr | ₹452 Cr | ₹503 Cr | +5.6% |
| EBITDA | ₹94.9 Cr | ₹58.9 Cr | ₹68.2 Cr | ₹75.9 Cr | ₹84.4 Cr | -2.9% |
| EBIT | ₹91.1 Cr | ₹53.7 Cr | ₹62.1 Cr | — | — | -9.1% |
| PAT | ₹67.2 Cr | ₹39.8 Cr | ₹45.0 Cr | ₹50.8 Cr | ₹57.9 Cr | -3.6% |
| EPS (diluted) | ₹23.03 | ₹13.63 | ₹15.56 | — | — | -9.3% |
| CFO | ₹52.2 Cr | ₹20.2 Cr | ₹27.9 Cr | ₹50.9 Cr | ₹36.0 Cr | -8.9% |
| CapEx | ₹-23.5 Cr | ₹-8.9 Cr | ₹-6.7 Cr | ₹-35.6 Cr | ₹-55.0 Cr | — |
| FCF | ₹28.7 Cr | ₹11.3 Cr | ₹21.2 Cr | ₹15.3 Cr | ₹-19.0 Cr | — |
| Total Assets | ₹350 Cr | ₹362 Cr | ₹367 Cr | ₹421 Cr | ₹509 Cr | +9.8% |
| Total Debt | ₹0.9 Cr | ₹0.9 Cr | ₹1.7 Cr | ₹2.1 Cr | ₹1.8 Cr | +19.2% |
| Shareholders' Equity | ₹265 Cr | ₹291 Cr | ₹288 Cr | ₹327 Cr | ₹370 Cr | +8.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AMRUTANJAN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
HESTERBIO HESTERBIO | — | — | Pending | 15.4% | 19.3× |
 VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
 WINDLAS WINDLAS | — | — | Pending | 12.1% | — |
 SAKAR SAKAR | — | — | Pending | 6.1% | — |
BETA BETA | — | — | Pending | 16.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
28 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹23.00/sh
Last payout
2026-02-06
₹1.00
Peak payout
₹2.60
Trailing yield
0.83%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AMRUTAJAN HEALTH LTD (AMRUTANJAN.NS) trades at 556.95 vs a model fair value of 358.49, a gap of -35.6%. Piotroski F-score: 6/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AMRUTANJAN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AMRUTANJAN →
Compare
Head-to-head with peers
Compare AMRUTANJAN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AMRUTANJANNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.